Hakkında Regenacy pharmaceuticals llc

Şirket hakkında

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Its compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with the first-in-class potential, currently positioned to enter Phase 2 clinical trials. Its investigation of ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function.